secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-07-27T11:07:30+00:00
Accession:  0001193125-26-316819
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Therapeutics reports favorable NMRA-215 toxicology results, plans IND in Q4 2026
--------------------------------------------------------------------------------

- Repeat 13-week rat toxicology study (162 animals) showed no unexpected adverse findings, resolving prior concerns from a study with 5 of 142 animals affected.
- Company plans to submit IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, in Q4 2026 and start Phase 1 by end of 2026.
- NMRA-215 demonstrated class-leading weight loss in diet-induced obesity mouse model, including additive effects with semaglutide and potential for switch/maintenance.
- For-cause audit of prior study revealed discrepancies; company believes prior adverse findings were not drug-related.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/0001193125-26-316819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/nmra-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer